362 related articles for article (PubMed ID: 19130220)
1. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
2. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
3. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
Zhang JX
PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
[TBL] [Abstract][Full Text] [Related]
4. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
5. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
6. Private expenditures on brand name prescription drugs after generic entry.
Balaban DY; Dhalla IA; Law MR; Bell CM
Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
[TBL] [Abstract][Full Text] [Related]
7. Impact of brand drug discount cards on private insurer, government and patient expenditures.
Law MR; Chan FKI; Harrison M; Worthington HC
CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
[TBL] [Abstract][Full Text] [Related]
8. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
9. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
10. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
11. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
12. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
13. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
14. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
15. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
Haas JS; Phillips KA; Gerstenberger EP; Seger AC
Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
[TBL] [Abstract][Full Text] [Related]
16. Prescription drug costs and the generic dispensing ratio.
Liberman JN; Roebuck MC
J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
[TBL] [Abstract][Full Text] [Related]
17. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
18. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
19. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
20. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
